The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention
Open accessAbstract
Gaucher disease is characterized by storage of glucosylceramide in lysosomes of tissue macrophages as the result of an autosomal recessively inherited deficiency in glucocerebrosidase. Progressive accumulation of these glycolipid-laden Gaucher cells causes a variety of debilitating symptoms. The disease can be effectively treated by costly intravenous infusions with recombinant glucocerebrosidase. Chitotriosidase is massively secreted by Gaucher cells and its plasma levels are used to monitor efficacy of enzyme therapy. Broad-scale application is hampered by the common genetic defect in this surrogate marker. We report that in plasma of symptomatic patients with Gaucher disease the chemokine CCL18 is on average 29-fold elevated, without overlap between patient and control values (median control plasma level is 33 ng/mL, range, 10-72 ng/mL; median Gaucher plasma level is 948 ng/mL, range, 237-2285 ng/mL). Plasma CCL18 concentrations decrease during therapy, comparably to chitotriosidase levels. Immunohistochemistry demonstrates that Gaucher cells are the prominent source of CCL18. Plasma CCL18 levels can serve as alternative surrogate marker for storage cells in patients with Gaucher disease and monitoring of plasma CCL18 levels proves to be useful in determination of therapeutic efficacy, especially in patients who are deficient in chitotriosidase activity. The potential physiologic consequences of chronically elevated CCL18 in patients with Gaucher disease are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Chemokines and leukocyte traffic
Baggiolini, M. (1998) · Nature · doi:10.1038/33340 · Cited by 2,709
The Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
Hollak, C. E., van Weely, S., van Oers, M. H., & Aerts, J. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117084 · Cited by 896 · cited 2×
“Obviously these individuals can not be monitored by the measurement of plasma chitotriosidase activity 5,10 .”
Self-citationCox, T., Lachmann, R., Hollak, C., Aerts, J., van Weely, S., Hrebícek, M., Platt, F., Butters, T., Dwek, R., Moyses, C., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02161-9 · Cited by 744
Self-citationChemokines and chemokine receptors in leukocyte trafficking
Olson, T. S., & Ley, K. (2002) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00738.2001 · Cited by 674
A dendritic-cell-derived C–C chemokine that preferentially attracts naive T cells
Adema, G. J., Hartgers, F., Verstraten, R., de Vries, E., Marland, G., Menon, S., Foster, J., Xu, Y., Nooyen, P., McClanahan, T., et al. (1997) · Nature · doi:10.1038/42716 · Cited by 523
The Human Chitotriosidase Gene
Boot, R. G., Renkema, G. H., Verhoek, M., Strijland, A., Bliek, J., de Meulemeester, T. M. A. M. O., Mannens, M. M. A. M., & Aerts, J. M. F. G. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25680 · Cited by 416
Self-citationGaucher Disease: Clinical, Laboratory, Radiologic, and Genetic Features of 53 Patients
Zimran, A., Kay, A., Gelbart, T., Garver, P., Thurston, D., Saven, A., & Beutler, E. (1992) · Medicine · doi:10.1097/00005792-199211000-00002 · Cited by 336
Cited by
Gaucher disease: pathological mechanisms and modern management
Jmoudiak, M., & Futerman, A. H. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05351.x · Cited by 288
Chahine, L. M., Qiang, J., Ashbridge, E., Minger, J., Yearout, D., Horn, S., Colcher, A., Hurtig, H. I., Lee, V. M.-Y., Van Deerlin, V. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1274 · Cited by 150
Hendrickx, D. A. E., van Scheppingen, J., van der Poel, M., Bossers, K., Schuurman, K. G., van Eden, C. G., Hol, E. M., Hamann, J., & Huitinga, I. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01810 · Cited by 139
Mattsson, N., Tabatabaei, S., Johansson, P., Hansson, O., Andreasson, U., Månsson, J.-E., Johansson, J.-O., Olsson, B., Wallin, A., Svensson, J., et al. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8147-9 · Cited by 118
Plasma chitotriosidase and CCL18: Early biochemical surrogate markers in type B Niemann‐Pick disease
Brinkman, J., Wijburg, F. A., Hollak, C. E., Groener, J. E., Verhoek, M., Scheij, S., Aten, J., Boot, R. G., & Aerts, J. M. (2005) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-005-4416-9 · Cited by 90
Self-citation
Metadata
- Authors
- Boot, R. G., Verhoek, M., de Fost, M., Hollak, C. E. M., Maas, M., Bleijlevens, B., van Breemen, M. J., van Meurs, M., Boven, L. A., Laman, J. D., Moran, M. T., Cox, T. M., & Aerts, J. M. F. G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-01-01
- Volume
- 103
- Issue
- 1
- Pages
- 33-39
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2097813811
- Cited by
- 334
- References
- 35
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. https://app.cochat.ai/papers/10.1182/blood-2003-05-1612
- The paper
- Boot, R. G., Verhoek, M., de Fost, M., Hollak, C. E. M., Maas, M., Bleijlevens, B., van Breemen, M. J., van Meurs, M., Boven, L. A., Laman, J. D., Moran, M. T., Cox, T. M., & Aerts, J. M. F. G. (2004). Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood. https://doi.org/10.1182/blood-2003-05-1612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
